BioAtla IPO Presentation Deck

AXL: Well-Validated Target Among Multiple Indications 1 Disease Progression AXL's higher expression associated with disease progression in several indications, including: - Sarcoma, NSCLC, ovarian cancer, breast cancer, pancreatic cancer, glioblastoma, melanoma, RCC, prostate cancer, and esophageal cancer Tumor type Sarcoma (STS & Bone) NSCLC Ovarian Cancer 2 Patient treatment phase Stage III/IV Stage III/IV (PD-1/L1 experienced) Stage III/IV Platinum resistant Tumor Resistance AXL expression associated with tumor resistance to: - Chemotherapy, PD- 1/L1 inhibitors, molecular targeted therapy, and radiation therapy 10,000-15,000 Initial US Addressable Patient Population Est. corresponding US patient population 66,000² 3 12,000 Clinical Validation AXL has been clinically validated as a target: - Multiple assets in the clinic including non-specific small molecules and antibody ADCs - Some anti-AXL antibodies in the clinic have shown encouraging signs of antitumor activity: however, adverse events may limit clinical utility and/or potency Est. AXL positivity rate¹ 50% 30% 30-40% Source: BioAtla IHC assay validation results & phase 1 AXL testing data, GlobalData-Opportunity Analysis and Forecasts, SEER database Based on TmPS (Tumor membrane Percent Score) 275% of these patients generally switch to a new therapy bigatla Est. US target population at launch 5,000-7,500 15,000 4,000 10

View entire presentation